PubMed:19048115 / 1214-1462 JSONTXT

{"project":"LitCoin-sentences","denotations":[{"id":"T8","span":{"begin":0,"end":248},"obj":"Sentence"}],"text":"As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines)."}

{"project":"LitCoin-entities","denotations":[{"id":"5577","span":{"begin":13,"end":19},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5578","span":{"begin":40,"end":43},"obj":"GeneOrGeneProduct"},{"id":"5579","span":{"begin":72,"end":76},"obj":"GeneOrGeneProduct"},{"id":"5580","span":{"begin":80,"end":84},"obj":"GeneOrGeneProduct"},{"id":"5581","span":{"begin":96,"end":99},"obj":"GeneOrGeneProduct"},{"id":"5582","span":{"begin":176,"end":180},"obj":"GeneOrGeneProduct"},{"id":"5583","span":{"begin":190,"end":196},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5584","span":{"begin":221,"end":224},"obj":"ChemicalEntity"},{"id":"5585","span":{"begin":231,"end":234},"obj":"GeneOrGeneProduct"}],"attributes":[{"id":"A27","pred":"db_id","subj":"5577","obj":"MESH:D009369"},{"id":"A28","pred":"db_id","subj":"5578","obj":"NCBIGene:4763"},{"id":"A29","pred":"db_id","subj":"5579","obj":"NCBIGene:3845"},{"id":"A30","pred":"db_id","subj":"5580","obj":"NCBIGene:673"},{"id":"A31","pred":"db_id","subj":"5581","obj":"NCBIGene:3845"},{"id":"A32","pred":"db_id","subj":"5582","obj":"NCBIGene:5594"},{"id":"A33","pred":"db_id","subj":"5583","obj":"MESH:D009369"},{"id":"A34","pred":"db_id","subj":"5584","obj":"MESH:D006160"},{"id":"A35","pred":"db_id","subj":"5585","obj":"NCBIGene:3845"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines)."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T52","span":{"begin":13,"end":19},"obj":"GeneOrGeneProduct"},{"id":"T53","span":{"begin":24,"end":28},"obj":"GeneOrGeneProduct"},{"id":"T54","span":{"begin":29,"end":34},"obj":"GeneOrGeneProduct"},{"id":"T55","span":{"begin":40,"end":43},"obj":"GeneOrGeneProduct"},{"id":"T56","span":{"begin":44,"end":51},"obj":"GeneOrGeneProduct"},{"id":"T57","span":{"begin":52,"end":58},"obj":"GeneOrGeneProduct"},{"id":"T58","span":{"begin":59,"end":68},"obj":"GeneOrGeneProduct"},{"id":"T59","span":{"begin":72,"end":76},"obj":"GeneOrGeneProduct"},{"id":"T60","span":{"begin":80,"end":84},"obj":"GeneOrGeneProduct"},{"id":"T61","span":{"begin":108,"end":118},"obj":"GeneOrGeneProduct"},{"id":"T62","span":{"begin":119,"end":124},"obj":"GeneOrGeneProduct"},{"id":"T63","span":{"begin":176,"end":180},"obj":"GeneOrGeneProduct"},{"id":"T64","span":{"begin":190,"end":196},"obj":"GeneOrGeneProduct"},{"id":"T65","span":{"begin":236,"end":240},"obj":"GeneOrGeneProduct"},{"id":"T66","span":{"begin":241,"end":246},"obj":"GeneOrGeneProduct"}],"text":"As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines)."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T29","span":{"begin":24,"end":28},"obj":"GeneOrGeneProduct"},{"id":"T30","span":{"begin":29,"end":34},"obj":"GeneOrGeneProduct"},{"id":"T31","span":{"begin":40,"end":43},"obj":"GeneOrGeneProduct"},{"id":"T32","span":{"begin":72,"end":76},"obj":"GeneOrGeneProduct"},{"id":"T33","span":{"begin":80,"end":84},"obj":"GeneOrGeneProduct"},{"id":"T34","span":{"begin":176,"end":180},"obj":"GeneOrGeneProduct"},{"id":"T35","span":{"begin":236,"end":240},"obj":"GeneOrGeneProduct"},{"id":"T36","span":{"begin":241,"end":246},"obj":"GeneOrGeneProduct"}],"text":"As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines)."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T8","span":{"begin":13,"end":19},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":190,"end":196},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A8","pred":"originalLabel","subj":"T8","obj":"D009369"},{"id":"A9","pred":"originalLabel","subj":"T9","obj":"D009369"}],"text":"As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines)."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T16","span":{"begin":40,"end":43},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":72,"end":76},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":80,"end":84},"obj":"GeneOrGeneProduct"},{"id":"T19","span":{"begin":176,"end":180},"obj":"GeneOrGeneProduct"}],"text":"As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines)."}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T15","span":{"begin":40,"end":43},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A15","pred":"mondo_id","subj":"T15","obj":"0018975"}],"text":"As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines)."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T14","span":{"begin":13,"end":19},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T16","span":{"begin":190,"end":196},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A14","pred":"ID:","subj":"T14","obj":"DISEASE"},{"id":"A15","pred":"ID:","subj":"T14","obj":"D009369"},{"id":"A16","pred":"ID:","subj":"T16","obj":"DISEASE"},{"id":"A17","pred":"ID:","subj":"T16","obj":"D009369"}],"text":"As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines)."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T13","span":{"begin":13,"end":19},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T14","span":{"begin":190,"end":196},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A13","pred":"#label","subj":"T13","obj":"D009369"},{"id":"A14","pred":"#label","subj":"T14","obj":"D009369"}],"text":"As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines)."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T1","span":{"begin":221,"end":224},"obj":"ChemicalEntity"}],"attributes":[{"id":"A1","pred":"ID:","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_37565"},{"id":"A2","pred":"ID:","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_15996"}],"text":"As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines)."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T1","span":{"begin":221,"end":224},"obj":"ChemicalEntity"},{"id":"T19","span":{"begin":176,"end":180},"obj":"GeneOrGeneProduct"},{"id":"T18","span":{"begin":80,"end":84},"obj":"GeneOrGeneProduct"},{"id":"T17","span":{"begin":72,"end":76},"obj":"GeneOrGeneProduct"},{"id":"T16","span":{"begin":40,"end":43},"obj":"GeneOrGeneProduct"},{"id":"T50555","span":{"begin":190,"end":196},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T53594","span":{"begin":13,"end":19},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A2","pred":"ID:","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_15996"},{"id":"A1","pred":"ID:","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_37565"},{"id":"A14","pred":"#label","subj":"T50555","obj":"D009369"},{"id":"A13","pred":"#label","subj":"T53594","obj":"D009369"}],"text":"As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines)."}

{"project":"PMID_GLOBAL","denotations":[{"id":"T15","span":{"begin":40,"end":43},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A15","pred":"mondo_id","subj":"T15","obj":"0018975"}],"text":"As expected, tumors and cell lines with NF1 defects lacked mutations in KRAS or BRAF but showed Ras pathway activation based on immunohistochemical detection of phosphorylated MAPK (primary tumors) or increased levels of GTP-bound Ras (cell lines)."}